

# Anti-IGF-1R (Teprotumumab), Human IgG1 Antibody

07/20

---

**CATALOG NO.:** A2160-100 (100 µg)
 

---

**BACKGROUND DESCRIPTION:** The research-grade biosimilar is a fully human IgG1 monoclonal antibody that binds to the  $\alpha$ -subunit domain of IGF-1R. IGF-1R is overexpressed in orbital fibroblasts of patients suffering from thyroid eye disease. Thyroid eye disease is a manifestation of Grave's disease that is associated with inflammation of orbital muscles and fatty tissues. Although the mechanism of action of the original drug has not yet been fully characterized, binding of the drug to IGF-1R has been reported to internalize and degrade the receptors, and thus inhibit tissue inflammation and remodeling associated with Thyroid eye disease. In 2020, the US FDA approved the application of the drug to treat Graves-associated ophthalmopathy

**ALTERNATE NAMES:** RO4858696-000, R-1507, RV-001, IGFR, CD221, IGFIR, JTK13

**ANTIBODY TYPE:** Monoclonal

**CONCENTRATION:** 1 mg/ml

**HOST/ISOTYPE:** Recombinant / IgG1

**SOURCE:** CHO cells

**IMMUNOGEN:** Human IGF-1R

**CAS NUMBER:** 1036734-93-6

**MOLECULAR WEIGHT:** 148 kDa

**PURIFICATION:** Protein A purified

**FORM:** Liquid

**FORMULATION:** In PBS, pH 7.5

**SPECIES REACTIVITY:** Human

**STORAGE CONDITIONS:** Store at -80°C

**This information is only intended as a guide. The optimal dilutions must be determined by the user**

**RELATED PRODUCTS:**

Anti-IgE (Omalizumab), Humanized Antibody (A2145)  
 Anti-VEGF-A Humanized Antibody (A2136)  
 Anti-IL-17 $\alpha$  (Ixekizumab), Humanized Antibody (A2149)  
 Anti-IL-6 receptor (Tocilizumab), Human IgG1 Antibody (A1447)  
 Anti-CD38 (Daratumumab), Human IgG1 Antibody (A2151)

**FOR RESEARCH USE ONLY! Not to be used on humans.**